Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anthracycline-induced cardiomyopathy.

D L Keefe1

  • 1Divisions of Cardiology and Critical Care, Memorial Sloan Kettering Center, New York, NY 10021, USA.

Seminars in Oncology
|September 12, 2001
PubMed
Summary

Anthracycline chemotherapy can cause heart damage (cardiomyopathy). Early detection and preventive strategies, including monitoring left ventricular function and using dexrazoxane, can significantly reduce cardiotoxicity in cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of follicular fluid and cumulus cells on oocyte quality: clinical implications.

Journal of assisted reproduction and genetics·2018
Same author

Peripheral blood telomere content is greater in patients with endometriosis than in controls.

Reproductive sciences (Thousand Oaks, Calif.)·2014
Same author

Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.

Journal of human hypertension·2012
Same author

Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2011
Same author

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.

Journal of human hypertension·2010
Same author

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.

Journal of human hypertension·2009

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Certain chemotherapeutic agents, including anthracyclines (doxorubicin, daunorubicin, etc.) and mitoxantrone, are associated with acute and chronic cardiotoxicity.
  • This cardiotoxicity manifests as dose-related cardiomyopathy, characterized by systolic dysfunction and mitral insufficiency, historically diagnosed via myocardial biopsy and radionuclide angiography.
  • Echocardiography is now the preferred, cost-effective diagnostic tool for assessing chemotherapy-induced cardiomyopathy.

Purpose of the Study:

  • To review the mechanisms, diagnosis, and management strategies for anthracycline-induced cardiotoxicity.
  • To emphasize the importance of prevention and early monitoring in mitigating long-term cardiac damage.
  • To discuss current therapeutic approaches for managing chemotherapy-related heart failure.

Main Methods:

  • Review of existing literature on anthracycline cardiotoxicity.
  • Discussion of diagnostic modalities, with emphasis on echocardiography.
  • Analysis of preventive measures, including drug level reduction and use of dexrazoxane.
  • Evaluation of therapeutic interventions for established cardiomyopathy.

Main Results:

  • Cardiomyopathy is a significant, cumulative, and often irreversible side effect of anthracycline chemotherapy.
  • Dexrazoxane, an iron chelator, can increase the maximum tolerated cumulative dose by reducing peak drug levels.
  • Regular monitoring of left ventricular function is crucial for early detection and prevention of severe cardiotoxicity.
  • Conventional heart failure therapies (ACE inhibitors, digoxin, diuretics) and specific agents like carvedilol and spironolactone show efficacy.

Conclusions:

  • Prevention is paramount due to the largely irreversible nature of anthracycline-induced cardiomyopathy.
  • Close monitoring of cardiac function, especially as patients approach toxic doses, can substantially reduce cardiotoxicity.
  • Advances in prevention and therapy have improved the long-term outlook for patients experiencing chemotherapy-related cardiomyopathy.

Related Experiment Videos